CAR-T cells targeting CD19 and B-cell maturation antigen (BCMA) have been approved by the U.S. FDA for the treatment of acute B-cell lymphocytic leukemia, certain types of lymphomas, and multiple myeloma (64, 65). This evidence concerns the gene TNFRSF17 and precursor B-cell acute lymphoblastic leukemia.